why choose us

First received: May 15, 2023

Clinical Trial: Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Transformed Chronic Lymphocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome

Brief Summary: This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome.Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma, which is a cancer of the lymph nodes.Zanubrutinib is a class of medication called a kinase inhibitor.These drugs work by preventing the action of abnormal proteins that tell cancer cells to multiply, which helps stop the…

Read more